About
H3Pelvic is developing Thermal Neuromodulation Therapy for pelvic health: a non-invasive, opioid-free and needle-free device for treating pelvic pain and dysfunction. Its research and development is backed by the NIH, Duke University and the North Carolina Department of Commerce. The device is investigational: it is not yet FDA cleared or available for commercial sale, and healthcare providers can request early access through a waitlist.
How you can help
Investigational. The device is not yet FDA cleared or available for commercial sale; healthcare providers can request early access through a waitlist.
- Healthcare providers interested in early access, to join the waitlist
- Clinicians and sites interested in taking part in future clinical trials
- Health-system and payer expertise to shape the reimbursement and value proposition
Key Information
- Founded
- 2024
- Team Size
- 1-5
- Funding Raised
- NIH SBIR Phase I + II (~$2.6M)
- Location
- Winston-Salem, NC
Recent Activity
Nov 12, 2026
H3Pelvic is in the Advisory5 Virtual ShowcaseSep 17, 2026
H3Pelvic wins $2.2M NIH SBIR Phase II grant ↗